Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate)
Clenbuterol
Clenbuterol is a medication used for the treatment of people with bronchial asthma, chronic bronchitis, emphysema, acute bronchitis, or stress urinary incontinence.
Physicians sometimes prescribe Clenbuterol for off-label treatment of people suffering from ALS.
Clenbuterol was previously known under the brand name TONIL (clenbuterol).
Kaftrio* (elexacaftor/tezacaftor/ivacaftor)
Kaftrio (elexacaftor/tezacaftor/ivacaftor)* is a medication used in combination with ivacaftor 150 mg tablets for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
Kalydeco* (ivacaftor)
Ketas (ibudilast)
Lucaftor (lumacaftor/ivacaftor)
Orkambi* (lumacaftor/ivacaftor)
Symdeko* (tezacaftor / ivacaftor)
Symdeko (tezacaftor/ivacaftor)* is a medicine for the treatment of patients with cystic fibrosis (CF) aged 6 years and older. It is available in tablet form each containing 100 mg of tezacaftor and 150 mg of ivacaftor. It is indicated in combination with another medicine containing 150 mg ivacaftor alone.
It is commercialized in Europe under the brand name Symkevi and in United States under the brand name Symdeko.
Symkevi* (tezacaftor/ivacaftor)
Symkevi (tezacaftor/ivacaftor)* is a medicine for the treatment of patients with cystic fibrosis (CF) aged 12 years and older. It is available in tablet form each containing 100 mg of tezacaftor and 150 mg of ivacaftor. It is indicated in combination with another medicine containing 150 mg ivacaftor alone.
It is commercialized in Europe under the brand name Symkevi and in United States under the brand name Symdeko.
Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol)
Trikafta* (elexacaftor/tezacaftor/ivacaftor; ivacaftor)
Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor)* is a medication used for the treatment of cystic fibrosis (CF), indicated for CF patients aged 12 years and older with certain mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that are responsive to Trikafta based on in vitro data.
